CSL Behring's Corifact Clears FDA On 14-Patient Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The orphan drug, for a rare blood disorder, is the latest in a history of drugs for ultra-orphan conditions.
You may also be interested in...
Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says
Advocates and drug developers continue to call for an Orphan Drug Act renovation – not to add more years of marketing exclusivity, but to consider allowing easier and cheaper development programs.
Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says
Advocates and drug developers continue to call for an Orphan Drug Act renovation – not to add more years of marketing exclusivity, but to consider allowing easier and cheaper development programs.
Orphan Drug Safety: FDA Asks How Much Pre-Approval Data Is Enough?
Agency's Advisory Committee for Pharmaceutical Science and Clinical Pharmacology will be asked to weigh pre-approval data requirements and discuss innovative approaches to boosting drug development for rare diseases at its March 2 meeting.